Neurosense Therapeutics Ltd. (NRSN) Gets a Buy Rating from Maxim Group

Maxim Group analyst Naz Rahman maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSNResearch Report) yesterday and set a price target of $7.00. The company’s shares closed last Tuesday at $2.49.

According to, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.3% and a 22.4% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Processa Pharmaceuticals, Vertex Pharmaceuticals, and Galmed Pharmaceuticals.

Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $8.18 and a one-year low of $1.23. Currently, Neurosense Therapeutics Ltd. has an average volume of 2.02M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Read More on NRSN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More